Gerull Brenda, Brodehl Andreas
Comprehensive Heart Failure Center Wuerzburg, Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.
Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada.
Front Physiol. 2020 Jun 24;11:624. doi: 10.3389/fphys.2020.00624. eCollection 2020.
Arrhythmogenic cardiomyopathy has been clinically defined since the 1980s and causes right or biventricular cardiomyopathy associated with ventricular arrhythmia. Although it is a rare cardiac disease, it is responsible for a significant proportion of sudden cardiac deaths, especially in athletes. The majority of patients with arrhythmogenic cardiomyopathy carry one or more genetic variants in desmosomal genes. In the 1990s, several knockout mouse models of genes encoding for desmosomal proteins involved in cell-cell adhesion revealed for the first time embryonic lethality due to cardiac defects. Influenced by these initial discoveries in mice, arrhythmogenic cardiomyopathy received an increasing interest in human cardiovascular genetics, leading to the discovery of mutations initially in desmosomal genes and later on in more than 25 different genes. Of note, even in the clinic, routine genetic diagnostics are important for risk prediction of patients and their relatives with arrhythmogenic cardiomyopathy. Based on improvements in genetic animal engineering, different transgenic, knock-in, or cardiac-specific knockout animal models for desmosomal and nondesmosomal proteins have been generated, leading to important discoveries in this field. Here, we present an overview about the existing animal models of arrhythmogenic cardiomyopathy with a focus on the underlying pathomechanism and its importance for understanding of this disease. Prospectively, novel mechanistic insights gained from the whole animal, organ, tissue, cellular, and molecular levels will lead to the development of efficient personalized therapies for treatment of arrhythmogenic cardiomyopathy.
致心律失常性心肌病自20世纪80年代起就有了临床定义,它会导致与室性心律失常相关的右心室或双心室心肌病。尽管它是一种罕见的心脏疾病,但在心脏性猝死中占相当大的比例,尤其是在运动员中。大多数致心律失常性心肌病患者在桥粒基因中携带一个或多个基因变异。在20世纪90年代,几个编码参与细胞间黏附的桥粒蛋白的基因敲除小鼠模型首次揭示了由于心脏缺陷导致的胚胎致死性。受小鼠这些初步发现的影响,致心律失常性心肌病在人类心血管遗传学中受到越来越多的关注,导致最初在桥粒基因中发现突变,后来在超过25个不同基因中发现突变。值得注意的是,即使在临床上,常规基因诊断对于致心律失常性心肌病患者及其亲属的风险预测也很重要。基于基因动物工程的改进,已经产生了针对桥粒和非桥粒蛋白的不同转基因、敲入或心脏特异性敲除动物模型,从而在该领域取得了重要发现。在此,我们概述了现有的致心律失常性心肌病动物模型,重点关注其潜在的发病机制及其对理解这种疾病的重要性。前瞻性地,从整体动物、器官、组织、细胞和分子水平获得的新的机制见解将导致开发出治疗致心律失常性心肌病的有效个性化疗法。